Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society's 38th Annual Scientific Sessions

Wednesday, April 12, 2017 Drug News
Email Print This Page Comment
Font : A-A+

Data from NODE-1 Trial to be Presented as Part of Late Breaking Oral Session May 11th

MONTREAL, April 12, 2017 /PRNewswire/ -- Milestone Pharmaceuticals Montreal, Canada,

Inc., a clinical stage cardiovascular company, today announced that data from its Phase 2 NODE-1 trial evaluating etripamil, a novel, potent, fast-acting and short-acting calcium channel blocker being developed for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT), a potentially debilitating cardiac arrhythmia, will be presented in a late-breaking oral presentation at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions taking place May 10-13, 2017 in Chicago.

Details for the NODE-1 Late-Breaking Oral Presentation at Heart Rhythm 2017:

Title: Intranasal Etripamil for Conversion of Paroxysmal Supraventricular Tachycardia (PSVT) – NODE-1 Trial     Presenter: Bruce Stambler, MD, FHRS, Piedmont Heart Institute, Atlanta, GA    Abstract Number: C-LBCT01-02    Session: Late Breaking Clinical Trials I    Location: McCormick Place – Room 375E    Date and Time: May 11, 2017, 8:15 – 8:30 AM

About Etripamil

Etripamil is a novel, potent, short-acting calcium channel blocker developed as a fast-acting nasal spray that can be administered by the patient to acutely terminate paroxysmal supraventricular tachycardia (PSVT) episodes wherever and whenever they occur. The Phase 2 clinical trial (NODE-1) has been successfully completed in the United States and Canada. Information regarding the NODE-1 clinical trial may be found at www.clinicaltrials.gov (study identifier NCT02296190). Etripamil is not approved for the treatment of PSVT or for any other indication anywhere in the world.

About Paroxysmal Supraventricular Tachycardia

Paroxysmal supraventricular tachycardia is a condition that afflicts approximately 1.7 million people and results in over 600,000 healthcare claims in the US alone per year. During a PSVT episode, patients may feel palpitations while heart rate increases dramatically and can exceed 200 beats per minute. Although the condition is not life threatening, it causes great concern on the part of the patient and can result in a visit to a hospital emergency room where the patient is usually administered intravenous drugs and observed until their symptoms resolve.

About Milestone Pharmaceuticals

Milestone, with headquarters in Montreal, Canada and a US subsidiary in Charlotte, NC, is a clinical stage drug development company developing novel small molecule therapeutics based on clinically validated mechanisms of action for cardiovascular diseases. Milestone's lead product, etripamil, is a novel, fast-acting and short-acting calcium channel blocker for the acute treatment of PSVT episodes. For more information, please visit www.milestonepharma.com.

Contact:

David PittsArgot Partners212-600-1902david@argotpartners.com  

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-etripamil-phase-2-data-at-the-heart-rhythm-societys-38th-annual-scientific-sessions-300438483.html

SOURCE Milestone Pharmaceuticals USA, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook